OGEN - Kapitalisasi marang volume dodolan oragenics.com

Logo korporat perusahaan Oragenics, Inc. (OGEN)

Oragenics, Inc. (OGEN) faces early-stage development risks and a capital deficit. The company is penetrating the niche of intranasal agents for brain injuries, where competition is absent. The price-to-sales ratio visualizes these processes, and its current value is 372.50. Geopolitical tensions and the need for new antibiotics could strengthen government support for the business.

Oragenics, Inc. (OGEN): Rasio rega marang pendapatan saka 04.07.2022 nganti 15.11.2024

Rincian metrik lan analitis perusahaan Oragenics, Inc. (OGEN)

- rega pasar lan target rega analis:
Kutipan saham Oragenics Inc.|OGEN - Target konsensus
- statistik kapitalisasi pasar:
Nilai pasar Oragenics|OGEN - Nilai Perusahaan
- informasi kapitalisasi buku:
Aset Bersih saben Saham Oragenics|OGEN - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku oragenics.com|OGEN - Aset Agregat Perusahaan
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas Oragenics, Inc.|OGEN - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal oragenics.com|OGEN - Utang perusahaan|Utang-utang marang nilai buku Oragenics|OGEN - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Oragenics|Rasio cepet oragenics.com
- data bathi resik lan rasio valuasi:
OGEN - Bathi resik|Proyeksi bathi resik Oragenics, Inc.|OGEN - Pangali P/E|Rasio prakiraan rega marang bathi Oragenics Inc.|OGEN - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Oragenics|OGEN - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Oragenics|OGEN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan oragenics.com|OGEN - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Oragenics, Inc.
- data total pendapatan lan volume dodolan:
OGEN - Dodolan perusahaan|Pendapatan mangsa ngarep perusahaan oragenics.com|OGEN - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Oragenics
Analisis fundamental perusahaan:OGEN - Oragenics Inc.
Produk sing diprodhuksi Oragenics, Inc.

The P/S ratio reflects the market value of a business relative to its annual revenue, allowing for an assessment of asset monetization efficiency regardless of current earnings. For the growing Oragenics, Inc. (OGEN), which develops neuroprotective agents, this revenue-based valuation on GURU.Markets demonstrates a premium for future success in sports medicine, where a historical analysis of the metric helps determine a fair entry threshold for capital protection.

Pesaing Oragenics, Inc.

Kapitalisasi marang pendapatan summittxinc.com SMMT|Moderna - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan PCVX (Vaxcyte Inc)|Tarsus Pharma - Multiplikator P/S|Koefisien rega marang pendapatan CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Rasio rega marang pendapatan|Rega marang dodolan sperotherapeutics.com (SPRO)|Rasio rega marang pendapatan SCYNEXIS Inc|Rasio kapitalisasi marang pendapatan ANTX (AN2 Bio)|Rasio rega marang pendapatan PolyPid Ltd. (PYPD)|Koefisien rega marang pendapatan YS Biopharma Co., Ltd.|Rasio rega marang pendapatan Iterum Therapeutics ITRM|BiomX Inc (PHGE) - Rega marang dodolan|SNGX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SXTP (60 Degrees Pharmaceuticals)|OPGN: Multiplikator P/S